-
1
-
-
19344364880
-
Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials
-
Early Breast Cancer Trialists' Collaborative Group (EBCTCG)
-
Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;365(9472):1687-1717.
-
(2005)
Lancet.
, vol.365
, Issue.9472
, pp. 1687-1717
-
-
-
2
-
-
4243063941
-
Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450system in vitro: Prominent roles for CYP3A and CYP2D6
-
Desta Z, Ward BA, Soukhova NV, Flockhart DA. Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004;310(3):1062-1075.
-
(2004)
J Pharmacol Exp Ther.
, vol.310
, Issue.3
, pp. 1062-1075
-
-
Desta, Z.1
Ward, B.A.2
Soukhova, N.V.3
Flockhart, D.A.4
-
3
-
-
67749114265
-
CYP2D6 and tamoxifen: DNA matters in breast cancer
-
Hoskins JM, Carey LA, McLeod HL. CYP2D6 and tamoxifen: DNA matters in breast cancer. Nat Rev Cancer. 2009;9(8):576-586.
-
(2009)
Nat Rev Cancer.
, vol.9
, Issue.8
, pp. 576-586
-
-
Hoskins, J.M.1
Carey, L.A.2
McLeod, H.L.3
-
4
-
-
80455168584
-
Evaluation of CYP2D6 and efficacy of tamoxifen and raloxifene in women treated for breast cancer chemoprevention: Results from the NSABP P1 and P2 clinical trials
-
Goetz MP, Schaid DJ, Wickerham DL, etal. Evaluation of CYP2D6 and efficacy of tamoxifen and raloxifene in women treated for breast cancer chemoprevention: results from the NSABP P1 and P2 clinical trials. Clin Cancer Res. 2011;17(21):6944-6951.
-
(2011)
Clin Cancer Res.
, vol.17
, Issue.21
, pp. 6944-6951
-
-
Goetz, M.P.1
Schaid, D.J.2
Wickerham, D.L.3
-
5
-
-
84859054082
-
CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients
-
ATAC trialists
-
Rae JM, Drury S, Hayes DF, etal; ATAC trialists. CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients. J Natl Cancer Inst. 2012;104(6):452-460.
-
(2012)
J Natl Cancer Inst.
, vol.104
, Issue.6
, pp. 452-460
-
-
Rae, J.M.1
Drury, S.2
Hayes, D.F.3
-
6
-
-
84859093970
-
CYP2D6genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: The breast international group 1-98 trial
-
Breast International Group (BIG) 1-98 Collaborative Group
-
Regan MM, Leyland-Jones B, Bouzyk M, etal; Breast International Group (BIG) 1-98 Collaborative Group. CYP2D6genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1-98 trial. J Natl Cancer Inst. 2012;104(6):441-451.
-
(2012)
J Natl Cancer Inst.
, vol.104
, Issue.6
, pp. 441-451
-
-
Regan, M.M.1
Leyland-Jones, B.2
Bouzyk, M.3
-
7
-
-
84875388654
-
Variants in tamoxifen metabolizing genes: A case-control study of contralateral breast cancer risk in the WECARE study
-
WECARE Study Collaborative Group
-
Brooks JD, Teraoka SN, Malone KE, etal; WECARE Study Collaborative Group, Bernstein JL, Figueiredo JC. Variants in tamoxifen metabolizing genes: a case-control study of contralateral breast cancer risk in the WECARE study. Int J Mol Epidemiol Genet. 2013;4(1):35-48.
-
(2013)
Int J Mol Epidemiol Genet.
, vol.4
, Issue.1
, pp. 35-48
-
-
Brooks, J.D.1
Teraoka, S.N.2
Malone, K.E.3
Bernstein, J.L.4
Figueiredo, J.C.5
-
8
-
-
0027221052
-
Metabolism of the antimammary cancer antiestrogenic agent tamoxifen. I. Cytochrome P-450-catalyzed N-demethylation and 4-hydroxylation
-
Mani C, Gelboin HV, Park SS, Pearce R, Parkinson A, Kupfer D. Metabolism of the antimammary cancer antiestrogenic agent tamoxifen. I. Cytochrome P-450-catalyzed N-demethylation and 4-hydroxylation. Drug Metab Dispos. 1993;21(4):645-656.
-
(1993)
Drug Metab Dispos.
, vol.21
, Issue.4
, pp. 645-656
-
-
Mani, C.1
Gelboin, H.V.2
Park, S.S.3
Pearce, R.4
Parkinson, A.5
Kupfer, D.6
-
9
-
-
79956196206
-
P-glycoprotein (ABCB1) transports the primary active tamoxifen metabolites endoxifen and 4-hydroxytamoxifen, and restricts their brain penetration
-
Iusuf D, Teunissen SF, Wagenaar E, Rosing H, Beijnen JH, Schinkel AH. P-glycoprotein (ABCB1) transports the primary active tamoxifen metabolites endoxifen and 4-hydroxytamoxifen, and restricts their brain penetration. J Pharmacol Exp Ther. 2011;337(3):710-717.
-
(2011)
J Pharmacol Exp Ther.
, vol.337
, Issue.3
, pp. 710-717
-
-
Iusuf, D.1
Teunissen, S.F.2
Wagenaar, E.3
Rosing, H.4
Beijnen, J.H.5
Schinkel, A.H.6
-
10
-
-
34547781742
-
Induction of multidrug resistance associated protein 2in tamoxifen-resistant breast cancer cells
-
Choi HK, Yang JW, Roh SH, Han CY, Kang KW. Induction of multidrug resistance associated protein 2in tamoxifen-resistant breast cancer cells. Endocr Relat Cancer. 2007;14(2):293-303.
-
(2007)
Endocr Relat Cancer.
, vol.14
, Issue.2
, pp. 293-303
-
-
Choi, H.K.1
Yang, J.W.2
Roh, S.H.3
Han, C.Y.4
Kang, K.W.5
-
11
-
-
0035197548
-
Identification of variants of CYP3A4 and characterization of their abilities to metabolize testosterone and chlorpyrifos
-
Dai D, Tang J, Rose R, etal. Identification of variants of CYP3A4 and characterization of their abilities to metabolize testosterone and chlorpyrifos. J Pharmacol Exp Ther. 2001;299(3):825-831.
-
(2001)
J Pharmacol Exp Ther.
, vol.299
, Issue.3
, pp. 825-831
-
-
Dai, D.1
Tang, J.2
Rose, R.3
-
12
-
-
0035217180
-
The genetic determinants of the CYP3A5 polymorphism
-
Hustert E, Haberl M, Burk O, etal. The genetic determinants of the CYP3A5 polymorphism. Pharmacogenetics. 2001;11(9): 773-779.
-
(2001)
Pharmacogenetics.
, vol.11
, Issue.9
, pp. 773-779
-
-
Hustert, E.1
Haberl, M.2
Burk, O.3
-
13
-
-
0041831261
-
Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus
-
Hesselink DA, van Schaik RH, van der Heiden IP, etal. Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus. Clin Pharmacol Ther. 2003;74(3):245-254.
-
(2003)
Clin Pharmacol Ther.
, vol.74
, Issue.3
, pp. 245-254
-
-
Hesselink, D.A.1
van Schaik, R.H.2
van der Heiden, I.P.3
-
14
-
-
33847249931
-
Influence of polymorphisms of ABCB1 and ABCC2 on mRNA and protein expression in normal and cancerous kidney cortex
-
Haenisch S, Zimmermann U, Dazert E, etal. Influence of polymorphisms of ABCB1 and ABCC2 on mRNA and protein expression in normal and cancerous kidney cortex. Pharmacogenomics J. 2007;7(1):56-65.
-
(2007)
Pharmacogenomics J.
, vol.7
, Issue.1
, pp. 56-65
-
-
Haenisch, S.1
Zimmermann, U.2
Dazert, E.3
-
15
-
-
33846504706
-
A "silent" polymorphism in the MDR1gene changes substrate specificity
-
Kimchi-Sarfaty C, Oh JM, Kim IW, etal. A "silent" polymorphism in the MDR1gene changes substrate specificity. Science. 2007;315(5811): 525-528.
-
(2007)
Science.
, vol.315
, Issue.5811
, pp. 525-528
-
-
Kimchi-Sarfaty, C.1
Oh, J.M.2
Kim, I.W.3
-
16
-
-
34248547635
-
MRP2 haplotypes confer differential susceptibility to toxic liver injury
-
Choi JH, Ahn BM, Yi J, etal. MRP2 haplotypes confer differential susceptibility to toxic liver injury. Pharmacogenet Genomics. 2007;17(6):403-415.
-
(2007)
Pharmacogenet Genomics.
, vol.17
, Issue.6
, pp. 403-415
-
-
Choi, J.H.1
Ahn, B.M.2
Yi, J.3
-
17
-
-
78649320874
-
Impact of ABCC2 haplotypes on transcriptional and posttranscriptional gene regulation and function
-
Laechelt S, Turrini E, Ruehmkorf A, Siegmund W, Cascorbi I, Haenisch S. Impact of ABCC2 haplotypes on transcriptional and posttranscriptional gene regulation and function. Pharmacogenomics J. 2011;11(1):25-34.
-
(2011)
Pharmacogenomics J.
, vol.11
, Issue.1
, pp. 25-34
-
-
Laechelt, S.1
Turrini, E.2
Ruehmkorf, A.3
Siegmund, W.4
Cascorbi, I.5
Haenisch, S.6
-
18
-
-
77956242845
-
CYP2D6 polymorphisms as predictors of outcome in breast cancer patients treated with tamoxifen: Expanded polymorphism coverage improves risk stratification
-
Schroth W, Hamann U, Fasching PA, etal. CYP2D6 polymorphisms as predictors of outcome in breast cancer patients treated with tamoxifen: expanded polymorphism coverage improves risk stratification. Clin Cancer Res. 2010;16(17):4468-4477.
-
(2010)
Clin Cancer Res.
, vol.16
, Issue.17
, pp. 4468-4477
-
-
Schroth, W.1
Hamann, U.2
Fasching, P.A.3
-
19
-
-
79955485361
-
Tamoxifen metabolite concentrations, CYP2D6genotype, and breast cancer outcomes
-
Madlensky L, Natarajan L, Tchu S, etal. Tamoxifen metabolite concentrations, CYP2D6genotype, and breast cancer outcomes. Clin Pharmacol Ther. 2011;89(5):718-725.
-
(2011)
Clin Pharmacol Ther.
, vol.89
, Issue.5
, pp. 718-725
-
-
Madlensky, L.1
Natarajan, L.2
Tchu, S.3
-
20
-
-
47749105202
-
Association between CYP2D6 *10genotype and survival of breast cancer patients receiving tamoxifen treatment
-
Xu Y, Sun Y, Yao L, etal. Association between CYP2D6 *10genotype and survival of breast cancer patients receiving tamoxifen treatment. Ann Oncol. 2008;19(8):1423-1429.
-
(2008)
Ann Oncol.
, vol.19
, Issue.8
, pp. 1423-1429
-
-
Xu, Y.1
Sun, Y.2
Yao, L.3
-
21
-
-
77950502100
-
Significant effect of polymorphisms in CYP2D6 and ABCC2 on clinical outcomes of adjuvant tamoxifen therapy for breast cancer patients
-
Kiyotani K, Mushiroda T, Imamura CK, etal. Significant effect of polymorphisms in CYP2D6 and ABCC2 on clinical outcomes of adjuvant tamoxifen therapy for breast cancer patients. J Clin Oncol. 2010;28(8): 1287-1293.
-
(2010)
J Clin Oncol.
, vol.28
, Issue.8
, pp. 1287-1293
-
-
Kiyotani, K.1
Mushiroda, T.2
Imamura, C.K.3
-
22
-
-
80052665548
-
Association between genetic polymorphisms of CYP2D6 and outcomes in breast cancer patients with tamoxifen treatment
-
Park HS, Choi JY, Lee MJ, etal. Association between genetic polymorphisms of CYP2D6 and outcomes in breast cancer patients with tamoxifen treatment. J Korean Med Sci. 2011;26(8):1007-1013.
-
(2011)
J Korean Med Sci.
, vol.26
, Issue.8
, pp. 1007-1013
-
-
Park, H.S.1
Choi, J.Y.2
Lee, M.J.3
-
23
-
-
70349899258
-
No association between CYP2D6*10genotype and survival of node-negative Japanese breast cancer patients receiving adjuvant tamoxifen treatment
-
Toyama T, Yamashita H, Sugiura H, Kondo N, Iwase H, Fujii Y. No association between CYP2D6*10genotype and survival of node-negative Japanese breast cancer patients receiving adjuvant tamoxifen treatment. Jpn J Clin Oncol. 2009;39(10):651-656.
-
(2009)
Jpn J Clin Oncol.
, vol.39
, Issue.10
, pp. 651-656
-
-
Toyama, T.1
Yamashita, H.2
Sugiura, H.3
Kondo, N.4
Iwase, H.5
Fujii, Y.6
-
24
-
-
84874017348
-
Impact of CYP2D6 polymorphisms on tamoxifen responses of women with breast cancer: A microarray-based study in Thailand
-
Sukasem C, Sirachainan E, Chamnanphon M, etal. Impact of CYP2D6 polymorphisms on tamoxifen responses of women with breast cancer: a microarray-based study in Thailand. Asian Pac J Cancer Prev. 2012;13(9):4549-4553.
-
(2012)
Asian Pac J Cancer Prev.
, vol.13
, Issue.9
, pp. 4549-4553
-
-
Sukasem, C.1
Sirachainan, E.2
Chamnanphon, M.3
-
25
-
-
84878302608
-
Association of CYP2D6 and CYP2C19 polymorphisms and disease-free survival of Thai post-menopausal breast cancer patients who received adjuvant tamoxifen
-
Chamnanphon M, Pechatanan K, Sirachainan E, et al. Association of CYP2D6 and CYP2C19 polymorphisms and disease-free survival of Thai post-menopausal breast cancer patients who received adjuvant tamoxifen. Pharmgenomics Pers Med. 2013;6:37-48.
-
(2013)
Pharmgenomics Pers Med.
, vol.6
, pp. 37-48
-
-
Chamnanphon, M.1
Pechatanan, K.2
Sirachainan, E.3
-
26
-
-
61449171134
-
Genetic polymorphisms of CYP2D6*10 and CYP2C19*2, *3 are not associated with prognosis, endometrial thickness, or bone mineral density in Japanese breast cancer patients treated with adjuvant tamoxifen
-
Okishiro M, Taguchi T, Jin Kim S, Shimazu K, Tamaki Y, Noguchi S. Genetic polymorphisms of CYP2D6*10 and CYP2C19*2, *3 are not associated with prognosis, endometrial thickness, or bone mineral density in Japanese breast cancer patients treated with adjuvant tamoxifen. Cancer. 2009;115(5):952-961.
-
(2009)
Cancer.
, vol.115
, Issue.5
, pp. 952-961
-
-
Okishiro, M.1
Taguchi, T.2
Jin Kim, S.3
Shimazu, K.4
Tamaki, Y.5
Noguchi, S.6
-
27
-
-
36349024762
-
Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes
-
Schroth W, Antoniadou L, Fritz P, et al. Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes. J Clin Oncol. 2007;25(33):5187-5193.
-
(2007)
J Clin Oncol.
, vol.25
, Issue.33
, pp. 5187-5193
-
-
Schroth, W.1
Antoniadou, L.2
Fritz, P.3
-
28
-
-
79959684375
-
Analysis of CYP3A4 genetic polymorphisms in Han Chinese
-
Zhou Q, Yu X, Shu C, et al. Analysis of CYP3A4 genetic polymorphisms in Han Chinese. J Hum Genet. 2011;56(6):415-422.
-
(2011)
J Hum Genet.
, vol.56
, Issue.6
, pp. 415-422
-
-
Zhou, Q.1
Yu, X.2
Shu, C.3
-
30
-
-
79953848236
-
Impact of CYP2D6, CYP3A5, CYP2C9 and CYP2C19 polymorphisms on tamoxifen pharmacokinetics in Asian breast cancer patients
-
Lim JSL, Chen XA, Singh O, et al. Impact of CYP2D6, CYP3A5, CYP2C9 and CYP2C19 polymorphisms on tamoxifen pharmacokinetics in Asian breast cancer patients. Br J Clin Pharmacol. 2011;71(5):737-750.
-
(2011)
Br J Clin Pharmacol.
, vol.71
, Issue.5
, pp. 737-750
-
-
Lim, J.S.L.1
Chen, X.A.2
Singh, O.3
-
31
-
-
19944434201
-
CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment
-
Jin Y, Desta Z, Stearns V, et al. CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J Natl Cancer Inst. 2005;97(1):30-39.
-
(2005)
J Natl Cancer Inst.
, vol.97
, Issue.1
, pp. 30-39
-
-
Jin, Y.1
Desta, Z.2
Stearns, V.3
-
32
-
-
79955480679
-
Activity levels of tamoxifen metabolites at the estrogen receptor and the impact of genetic polymorphisms of phase I and II enzymes on their concentration levels in plasma
-
German Tamoxifen and AI Clinicians Group
-
Murdter TE, Schroth W, Bacchus-Gerybadze L, et al; German Tamoxifen and AI Clinicians Group, Eichelbaum M, Schwab M, Brauch H. Activity levels of tamoxifen metabolites at the estrogen receptor and the impact of genetic polymorphisms of phase I and II enzymes on their concentration levels in plasma. Clin Pharmacol Ther. 2011;89(5):708-717.
-
(2011)
Clin Pharmacol Ther.
, vol.89
, Issue.5
, pp. 708-717
-
-
Murdter, T.E.1
Schroth, W.2
Bacchus-Gerybadze, L.3
Eichelbaum, M.4
Schwab, M.5
Brauch, H.6
-
33
-
-
33644639136
-
Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes
-
Goetz M, Rae J, Suman V, et al. Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. J Clin Oncol. 2005;23(36):9312-9318.
-
(2005)
J Clin Oncol.
, vol.23
, Issue.36
, pp. 9312-9318
-
-
Goetz, M.1
Rae, J.2
Suman, V.3
-
34
-
-
10444221019
-
Polymorphisms in cytochrome P4503A5 (CYP3A5) may be associated with race and tumor characteristics, but not metabolism and side effects of tamoxifen in breast cancer patients
-
Tucker AN, Tkaczuk KA, Lewis LM, Tomic D, Lim CK, Flaws JA. Polymorphisms in cytochrome P4503A5 (CYP3A5) may be associated with race and tumor characteristics, but not metabolism and side effects of tamoxifen in breast cancer patients. Cancer Lett. 2005;217(1): 61-72.
-
(2005)
Cancer Lett.
, vol.217
, Issue.1
, pp. 61-72
-
-
Tucker, A.N.1
Tkaczuk, K.A.2
Lewis, L.M.3
Tomic, D.4
Lim, C.K.5
Flaws, J.A.6
-
35
-
-
77953679656
-
Associations between tamoxifen, estrogens, and FSH serum levels during steady state tamoxifen treatment of postmenopausal women with breast cancer
-
Gjerde J, Geisler J, Lundgren S, etal. Associations between tamoxifen, estrogens, and FSH serum levels during steady state tamoxifen treatment of postmenopausal women with breast cancer. BMC Cancer. 2010;10(1):313.
-
(2010)
BMC Cancer.
, vol.10
, Issue.1
, pp. 313
-
-
Gjerde, J.1
Geisler, J.2
Lundgren, S.3
-
36
-
-
84862930465
-
Assessment of the impact of CYP3A polymorphisms on the formation of α-hydroxytamoxifen and N-desmethyltamoxifen in human liver microsomes
-
Mugundu GM, Sallans L, Guo Y, Shaughnessy EA, Desai PB. Assessment of the impact of CYP3A polymorphisms on the formation of α-hydroxytamoxifen and N-desmethyltamoxifen in human liver microsomes. Drug Metab Dispos. 2012;40(2):389-396.
-
(2012)
Drug Metab Dispos.
, vol.40
, Issue.2
, pp. 389-396
-
-
Mugundu, G.M.1
Sallans, L.2
Guo, Y.3
Shaughnessy, E.A.4
Desai, P.B.5
-
37
-
-
2342429738
-
The role of cytochrome P450 in cytotoxic bioactivation: Future therapeutic directions
-
Rooney PH, Telfer C, McFadyen MC, Melvin WT, Murray GI. The role of cytochrome P450 in cytotoxic bioactivation: future therapeutic directions. Curr Cancer Drug Targets. 2004;4(3):257-265.
-
(2004)
Curr Cancer Drug Targets.
, vol.4
, Issue.3
, pp. 257-265
-
-
Rooney, P.H.1
Telfer, C.2
McFadyen, M.C.3
Melvin, W.T.4
Murray, G.I.5
-
38
-
-
77955807020
-
Profiling the expression of cytochrome P450 in breast cancer
-
Murray GI, Patimalla S, Stewart KN, Miller ID, Heys SD. Profiling the expression of cytochrome P450 in breast cancer. Histopathology. 2010;57(2):202-211.
-
(2010)
Histopathology.
, vol.57
, Issue.2
, pp. 202-211
-
-
Murray, G.I.1
Patimalla, S.2
Stewart, K.N.3
Miller, I.D.4
Heys, S.D.5
-
39
-
-
84869839802
-
Evaluation of the C3435T polymorphism in the MDR1 gene in patients with hepatocellular carcinoma
-
Baldissera VD, de Mattos AA, Coral GP, et al. Evaluation of the C3435T polymorphism in the MDR1 gene in patients with hepatocellular carcinoma. Ann Hepatol. 2012;11(6):899-906.
-
(2012)
Ann Hepatol.
, vol.11
, Issue.6
, pp. 899-906
-
-
Baldissera, V.D.1
de Mattos, A.A.2
Coral, G.P.3
-
40
-
-
0041627670
-
Polymorphism C3435T of the MDR-1 gene predicts response to preoperative chemotherapy in locally advanced breast cancer
-
Kafka A, Sauer G, Jaeger C, et al. Polymorphism C3435T of the MDR-1 gene predicts response to preoperative chemotherapy in locally advanced breast cancer. Int J Oncol. 2003;22(5):1117-1121.
-
(2003)
Int J Oncol.
, vol.22
, Issue.5
, pp. 1117-1121
-
-
Kafka, A.1
Sauer, G.2
Jaeger, C.3
-
41
-
-
60549112572
-
Association of the ABCB1 gene polymorphisms 2677G. T/A and 3435C. T with clinical outcomes of paclitaxel monotherapy in metastatic breast cancer patients
-
Chang H, Rha SY, Jeung H-C, et al. Association of the ABCB1 gene polymorphisms 2677G. T/A and 3435C. T with clinical outcomes of paclitaxel monotherapy in metastatic breast cancer patients. Ann Oncol. 2009;20(2):272-277.
-
(2009)
Ann Oncol.
, vol.20
, Issue.2
, pp. 272-277
-
-
Chang, H.1
Rha, S.Y.2
Jeung, H.-C.3
-
42
-
-
0036731995
-
MDR1 gene polymorphisms affect therapy outcome in acute myeloid leukemia patients
-
Illmer T, Schuler US, Thiede C, et al. MDR1 gene polymorphisms affect therapy outcome in acute myeloid leukemia patients. Cancer Res. 2002;62(17):4955-4962.
-
(2002)
Cancer Res.
, vol.62
, Issue.17
, pp. 4955-4962
-
-
Illmer, T.1
Schuler, U.S.2
Thiede, C.3
|